Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.92 USD -0.40% Intraday chart for Revance Therapeutics, Inc. -5.20% -44.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data DJ
Revance Therapeutics Prices $100 Million Public Offering MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024 CI
Revance Therapeutics, Inc. Announces Executive Changes CI
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Revance Therapeutics Gets Permanent J-Code for Daxxify DJ
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals RE
North American Morning Briefing : Microsoft Kicks -2- DJ
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16 MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30 MT
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling MT
US Consumer group seeks stronger warnings on Botox, similar treatments RE
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating MT
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Revance Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Chart Revance Therapeutics, Inc.
More charts
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings. The Company's aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company's therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
4.92 USD
Average target price
16.33 USD
Spread / Average Target
+231.98%
Consensus
  1. Stock
  2. Equities
  3. Stock Revance Therapeutics, Inc. - Nasdaq
  4. News Revance Therapeutics, Inc.
  5. Revance Therapeutics : Wells Fargo Downgrades Revance Therapeutics to Equal-Weight From Overweight; Price Target is $17